Gliosarcoma is a rare tumor of the central nervous system, consisting of gliomatous and sarcomatous elements. The glioblastoma can undergo a change in phenotype, transforming into a gliosarcoma, especially when the tumor has been treated with radiotherapy. Features unique to gliosarcoma compared to glioblastoma include their potential to appear similar to a meningioma at macroscopy, repeated reports of metastases and infrequency of EGFR mutations. We present a case of secondary gliosarcoma to emphasize on the specificities, essentially diagnostical of this rare entity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annpat.2012.01.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secondary IDH-mutant gliosarcoma in a patient with prior IDH-mutant grade 2 astrocytoma.
J Neuropathol Exp Neurol
December 2024
Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors.
Cancer Med
November 2024
Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Purpose: This study describes oncological outcomes and investigates prognostic factors for patients with gliosarcomas (GSM).
Methods: Histopathologically confirmed GSM patients who underwent treatment at five European institutions were retrospectively analyzed.
Results: We analyzed 170 patients with a median clinical follow-up time of 9.
Purpose: National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) was a multicohort phase 2 trial that assigned patients with advanced pretreated cancers to molecularly targeted therapies on the basis of tumor genomic testing. NCI-MATCH Arm A evaluated afatinib, an EGFR tyrosine kinase inhibitor (TKI) approved for advanced non-small cell lung cancer, in patients with tumors other than lung cancer harboring mutations.
Methods: Patients with advanced pretreated cancers other than lung cancer found to have selected actionable mutations were offered participation in Arm A.
Metastatic glioblastoma to the lungs: a case report and literature review.
CNS Oncol
June 2024
Department of Neurology, Division of Neuro-Oncology, University of California, Irvine, CA 92868, USA.
Glioblastoma is the most common malignant primary brain tumor. Despite its infiltrative nature, extra-cranial glioblastoma metastases are rare. We present a case of a 63-year-old woman with metastatic glioblastoma in the lungs.
View Article and Find Full Text PDFTransformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Folia Neuropathol
May 2024
Department of Pathomorphology, Center of Postgraduate Medical Education, Warsaw, Poland.
Article Synopsis
- Gliosarcoma (GS) is a rare and serious type of brain tumor, considered grade 4 by doctors.
- It can either develop on its own or come from another brain tumor called glioblastoma.
- In a case study, a 51-year-old patient had glioblastoma that changed into gliosarcoma 16 months after the initial diagnosis, and tracking these cases can help improve treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!